Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

Launched by UNIVERSITY HOSPITAL, ANGERS · Jun 18, 2021

Keywords

ClinConnect Summary

This clinical trial, called CALRSUIVI, is looking into how tracking the CALR allele burden—essentially a measure of a specific genetic change—can help doctors diagnose and monitor patients with certain blood disorders known as myeloproliferative neoplasms. These conditions, which include essential thrombocythemia and primary myelofibrosis, can cause the body to produce too many blood cells. By understanding how this genetic marker changes over time, researchers hope to improve the way these diseases are managed.

To participate in this study, you need to be an adult (18 years or older) who has been diagnosed with a CALR mutated myeloproliferative neoplasm between 2006 and 2020. You should also have a sample available from the time of your diagnosis or before starting treatment and be willing to give consent to join the study. Participants can expect to contribute to important research that may lead to better monitoring of their condition. It's important to note that individuals with other active blood cancers or those unable to give consent are not eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adults (age ≥18 years),
• • affiliated to the national social security system,
• • with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,
• • for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,
• • who signed the consent to participate in the study,
• • included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).
• Exclusion Criteria:
• • patient with another active hematological disease or cancer at the time of diagnosis,
• • person subject to legal protection scheme or incapable of giving consent.